By continuing to use the site you agree to our Privacy & Cookies policy

Lung cancer drugs erlotinib and gefitinib under review by NICE

The National Institute for Health and Care Excellence is reviewing its guidance on the use of two lung cancer drugs – erlotinib and gefitinib – in response to changing clinical practice.

REGISTER FREE
TO CONTINUE READING

  • Access to limited news stories
  • Customised email alerts straight to your inbox (over 30 to choose from)

SUBSCRIBE
(for full online access)

  • Unlimited online access
  • Customised email alerts
  • Weekly delivery of NT magazine
  • 4,500 practice articles in our archive
  • £500+ worth of CPD learning units
  • Only 22p per day
Already registered?
To check that you are registered please enter your email address below

Our records show you are already a registered user. Please sign-in with your password.

By continuing to use the site you agree to our Privacy & Cookies policy

newsletterpromo